Deramiocel (CAP-1002)

Name: Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Clinical presentation - signs and symptoms
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Manufacturer: Capricor Therapeutics
Regulatory submission: Class 2 BLA resubmission submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Clinical presentation - signs and symptoms

3 evidence topics · 3 sources

Motor symptoms: childhood-onset progressive muscle weakness

“In boys with Duchenne muscular dystrophy, muscle weakness tends to appear in early childhood and worsen rapidly.” (opens the source at this quote in a new tab)

Cardiac manifestations: cardiomyopathy

“Development of cardiomyopathy affects all DMD patients” (opens the source at this quote in a new tab)

Cognitive and psychiatric manifestations

“High rates of intellectual disability (17–27%), learning disabilities (26%), autism spectrum disorder (15%), attention-deficit hyperactivity disorder (32%), and anxiety (27%)” (opens the source at this quote in a new tab)